Cumberland Pharmaceuticals (CPIX) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Evolus (EOLS) over the past year, gaining 90.2% versus a gain of 25.6%. Over five years, CPIX leads with a +154.7% price change compared with +1.7% for EOLS. Evolus is the larger company by market cap ($515.2 million vs $104.6 million), about 4.9 times the size.
On valuation, Evolus trades at a lower forward P/E (26.7x vs 49.9x for Cumberland Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | EOLS |
|---|---|---|
| Share price | $6.98 | $7.80 |
| Market cap | $104.58M | $515.19M |
| 1-day change | +1.31% | +0.78% |
| YTD return | +75.38% | +17.29% |
| 1-year return | +90.19% | +25.60% |
| 5-year return | +154.74% | +1.69% |
| Forward P/E | 49.86 | 26.67 |
| EPS (TTM) | $-0.62 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.28 | $9.31 |
| 52-week low | $1.85 | $3.86 |
| Distance from 52-week high | -24.78% | -16.22% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +92.31% |
| Average volume | 87.71K | 900.79K |
| Shares outstanding | 14.98M | 66.05M |
| Employees | 88 | 353 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evolus is about 4.9 times larger than Cumberland Pharmaceuticals by market value ($515.19M vs $104.58M).
- CPIX has outperformed EOLS by 64.6 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
CPIX vs EOLS FAQ
Which is bigger, Cumberland Pharmaceuticals or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $104.58M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CPIX or EOLS?
CPIX returned +90.19% over the past 12 months, compared with +25.60% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.